Syntheses of PDE3A inhibitor ORG9935 and determination of the absolute stereochemistries of its enantiomers by X-ray crystallography.

Tetrahedron

Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, Minneapolis, MN 55414, United States.

Published: May 2018

Two synthetic methods were developed for the synthesis of PDE3A inhibitor ORG9935. The first one proceeds in six steps and 34% overall yield and the second one in five steps and an overall yield of 69% starting from commercially available starting material 5,6-dimethoxybenzo[]thiophene-2-carboxylic acid (). The enantiomers of ORG9935 were separated by chiral column chromatography and the absolute stereochemistry of the (+)-enantiomer, ORG20865 was determined by X-ray crystallography to possess the (-configuration. The (-)-enantiomer, ORG20864, was therefore assigned the (-stereochemistry. The biologically less active (+)-isomer ORG20865 was converted to racemic ORG9935 under basic conditions, which then can be separated again into the enantiomers. The crystal structure of ORG20865 is notable for having the highest Z' for any known pharmaceutical substance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223663PMC
http://dx.doi.org/10.1016/j.tet.2018.04.045DOI Listing

Publication Analysis

Top Keywords

pde3a inhibitor
8
inhibitor org9935
8
x-ray crystallography
8
syntheses pde3a
4
org9935
4
org9935 determination
4
determination absolute
4
absolute stereochemistries
4
stereochemistries enantiomers
4
enantiomers x-ray
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!